CVAC Quote, Financials, Valuation and Earnings

BioNTech SE has a net margin of 68.44% compared to CureVac NV's net margin of 15.91%. CureVac NV's return on equity of 21.3% beat BioNTech SE's return on equity of -2.35%.

CureVac NV has a consensus price target of $7.30, signalling upside risk potential of 78.16%. On the other hand BioNTech SE has an analysts' consensus of $137.63 which suggests that it could grow by 22.97%. Given that CureVac NV has higher upside potential than BioNTech SE, analysts believe CureVac NV is more attractive than BioNTech SE.

CureVac NV has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison BioNTech SE has a beta of 0.182, suggesting its less volatile than the S&P 500 by 81.764%.

CureVac NV has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. BioNTech SE offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. CureVac NV pays -- of its earnings as a dividend. BioNTech SE pays out -- of its earnings as a dividend.

CureVac NV quarterly revenues are $543.2M, which are smaller than BioNTech SE quarterly revenues of $1.4B. CureVac NV's net income of $371.8M is higher than BioNTech SE's net income of $217.9M. Notably, CureVac NV's price-to-earnings ratio is 7.48x while BioNTech SE's PE ratio is 191.55x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CureVac NV is 1.54x versus 8.18x for BioNTech SE. Usually stocks with elevated PS ratios are considered overvalued.

InflaRx NV has a net margin of 68.44% compared to CureVac NV's net margin of -14092.9%. CureVac NV's return on equity of 21.3% beat InflaRx NV's return on equity of -61.55%.

CureVac NV has a consensus price target of $7.30, signalling upside risk potential of 78.16%. On the other hand InflaRx NV has an analysts' consensus of $8.06 which suggests that it could grow by 217.29%. Given that InflaRx NV has higher upside potential than CureVac NV, analysts believe InflaRx NV is more attractive than CureVac NV.

CureVac NV has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison InflaRx NV has a beta of 1.657, suggesting its more volatile than the S&P 500 by 65.659%.

CureVac NV has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. InflaRx NV offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. CureVac NV pays -- of its earnings as a dividend. InflaRx NV pays out -- of its earnings as a dividend.

CureVac NV quarterly revenues are $543.2M, which are larger than InflaRx NV quarterly revenues of $136.2K. CureVac NV's net income of $371.8M is higher than InflaRx NV's net income of -$19.2M. Notably, CureVac NV's price-to-earnings ratio is 7.48x while InflaRx NV's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CureVac NV is 1.54x versus 810.37x for InflaRx NV. Usually stocks with elevated PS ratios are considered overvalued.

Moderna has a net margin of 68.44% compared to CureVac NV's net margin of 0.7%. CureVac NV's return on equity of 21.3% beat Moderna's return on equity of -17.44%.

CureVac NV has a consensus price target of $7.30, signalling upside risk potential of 78.16%. On the other hand Moderna has an analysts' consensus of $68.01 which suggests that it could grow by 99.66%. Given that Moderna has higher upside potential than CureVac NV, analysts believe Moderna is more attractive than CureVac NV.

CureVac NV has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Moderna has a beta of 1.597, suggesting its more volatile than the S&P 500 by 59.715%.

CureVac NV has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Moderna offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. CureVac NV pays -- of its earnings as a dividend. Moderna pays out -- of its earnings as a dividend.

CureVac NV quarterly revenues are $543.2M, which are smaller than Moderna quarterly revenues of $1.9B. CureVac NV's net income of $371.8M is higher than Moderna's net income of $13M. Notably, CureVac NV's price-to-earnings ratio is 7.48x while Moderna's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CureVac NV is 1.54x versus 2.61x for Moderna. Usually stocks with elevated PS ratios are considered overvalued.

Pfizer has a net margin of 68.44% compared to CureVac NV's net margin of 25.23%. CureVac NV's return on equity of 21.3% beat Pfizer's return on equity of 4.63%.

CureVac NV has a consensus price target of $7.30, signalling upside risk potential of 78.16%. On the other hand Pfizer has an analysts' consensus of $31.18 which suggests that it could grow by 18.54%. Given that CureVac NV has higher upside potential than Pfizer, analysts believe CureVac NV is more attractive than Pfizer.

CureVac NV has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Pfizer has a beta of 0.644, suggesting its less volatile than the S&P 500 by 35.588%.

CureVac NV has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pfizer offers a yield of 6.39% to investors and pays a quarterly dividend of $0.42 per share. CureVac NV pays -- of its earnings as a dividend. Pfizer pays out 436.39% of its earnings as a dividend.

CureVac NV quarterly revenues are $543.2M, which are smaller than Pfizer quarterly revenues of $17.7B. CureVac NV's net income of $371.8M is lower than Pfizer's net income of $4.5B. Notably, CureVac NV's price-to-earnings ratio is 7.48x while Pfizer's PE ratio is 35.54x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CureVac NV is 1.54x versus 2.52x for Pfizer. Usually stocks with elevated PS ratios are considered overvalued.